TXG · Company research
10x Genomics, Inc. Class A Common Stock (TXG): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
27records availableTechnology
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| (TXG) Technical Pivots with Risk Controls (TXG:CA) - Stock Traders Daily | (TXG) Technical Pivots with Risk Controls (TXG:CA) Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 20, 2026 | neutral | 0 | 0.6 |
| TXG Stock Drops 13% As 10x Genomics Faces Sharp Selloff - Timothy Sykes | TXG Stock Drops 13% As 10x Genomics Faces Sharp Selloff Timothy Sykes | View source ↗ | Timothy Sykes | Oct 18, 2026 | neutral | 0 | 0.6 |
| 10x Genomics (TXG) Stock Fair Value Rises After Analysts Back AI And Atera Demand - Yahoo Finance | 10x Genomics (TXG) Stock Fair Value Rises After Analysts Back AI And Atera Demand Yahoo Finance | View source ↗ | Yahoo Finance | Oct 16, 2026 | neutral | 0 | 0.6 |
| 3 Reasons to Sell TXG and 1 Stock to Buy Instead - The Globe and Mail | 3 Reasons to Sell TXG and 1 Stock to Buy Instead The Globe and Mail | View source ↗ | The Globe and Mail | Oct 15, 2026 | neutral | 0 | 0.6 |
| 10x Genomics (TXG) Stock May Be Overvalued On Current Sales - Simply Wall Street | 10x Genomics (TXG) Stock May Be Overvalued On Current Sales Simply Wall Street | View source ↗ | Simply Wall Street | Oct 14, 2026 | neutral | 0 | 0.6 |
| 10x Genomics (NasdaqGS:TXG) Stock Forecast & Analyst Predictions - Simply Wall Street | 10x Genomics (NasdaqGS:TXG) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 14, 2026 | neutral | 0 | 0.6 |
| A public call on 10x Genomics' results is scheduled for Nov. 5, with a live webcast. - Stock Titan | A public call on 10x Genomics' results is scheduled for Nov. 5, with a live webcast. Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| 10x Genomics Inc (TXG) Shares Fall 6.8% -- What GF Score of 57 T - GuruFocus | 10x Genomics Inc (TXG) Shares Fall 6.8% -- What GF Score of 57 T GuruFocus | View source ↗ | GuruFocus | Oct 12, 2026 | neutral | 0 | 0.6 |
| 10x Genomics, Inc. (TXG) stock price, news, quote and history - Yahoo Finance Singapore | 10x Genomics, Inc. (TXG) stock price, news, quote and history Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Oct 11, 2026 | neutral | 0 | 0.6 |
| 10x Genomics, Inc. (TXG) Stock Price, News, Quote & History - Yahoo! Finance Canada | 10x Genomics, Inc. (TXG) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 11, 2026 | neutral | 0 | 0.6 |
| Why Did 10x Genomics (TXG) Stock Climb Today? - Simply Wall Street | Why Did 10x Genomics (TXG) Stock Climb Today? Simply Wall Street | View source ↗ | Simply Wall Street | Oct 10, 2026 | neutral | 0 | 0.6 |
| Why Are 10x Genomics (TXG) Shares Soaring Today - The Globe and Mail | Why Are 10x Genomics (TXG) Shares Soaring Today The Globe and Mail | View source ↗ | The Globe and Mail | Oct 9, 2026 | neutral | 0 | 0.6 |
| 10x Genomics (TXG) Institutional Ownership 2026 $TXG - MarketBeat | 10x Genomics (TXG) Institutional Ownership 2026 $TXG MarketBeat | View source ↗ | MarketBeat | Oct 9, 2026 | neutral | 0 | 0.6 |
| 10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research | 10x Genomics announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance single-cell and spatial technologies for biomarker discovery in bladder cancer and residual disease detection in acute myeloid leukemia. The company will utilize its Flex Apex and Xenium platforms to identify treatment response markers. Despite the strategic partnership, TXG stock declined 5.6% following the announcement, though it has gained 366.6% year-to-date. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| 10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research | 10x Genomics announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance single-cell and spatial technologies for biomarker discovery in bladder cancer and residual disease detection in acute myeloid leukemia. The company will utilize its Flex Apex and Xenium platforms to identify treatment response markers. Despite the strategic partnership, TXG stock declined 5.6% following the announcement, though it has gained 366.6% year-to-date. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| 10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research | 10x Genomics announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance single-cell and spatial technologies for biomarker discovery in bladder cancer and residual disease detection in acute myeloid leukemia. The company will utilize its Flex Apex and Xenium platforms to identify treatment response markers. Despite the strategic partnership, TXG stock declined 5.6% following the announcement, though it has gained 366.6% year-to-date. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 1 | 1 |
| TXG Stock Price and Chart — NASDAQ:TXG - TradingView | TXG Stock Price and Chart — NASDAQ:TXG TradingView | View source ↗ | TradingView | Oct 6, 2026 | neutral | 0 | 0.6 |
| Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation | The global microfluidics market is projected to grow from $21.58 billion in 2025 to $48.04 billion by 2036, with a CAGR of 7.49%. Growth is driven by rising demand for rapid diagnostics, point-of-care testing, genomic analysis, and automated workflows. Microfluidic consumables dominate with 66.7% market share, while Asia-Pacific is expected to register the highest regional growth at 8.72% CAGR. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bullish | 1 | 1 |
| Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation | The global microfluidics market is projected to grow from $21.58 billion in 2025 to $48.04 billion by 2036, with a CAGR of 7.49%. Growth is driven by rising demand for rapid diagnostics, point-of-care testing, genomic analysis, and automated workflows. Microfluidic consumables dominate with 66.7% market share, while Asia-Pacific is expected to register the highest regional growth at 8.72% CAGR. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bullish | 1 | 1 |
| 10x Genomics (TXG) Stock Is Up, What You Need To Know - Yahoo Finance | 10x Genomics (TXG) Stock Is Up, What You Need To Know Yahoo Finance | View source ↗ | Yahoo Finance | Sep 28, 2026 | neutral | 0 | 0.6 |
| 10x Genomics (TXG) Stock Is Up, What You Need To Know - TradingView | 10x Genomics (TXG) Stock Is Up, What You Need To Know TradingView | View source ↗ | TradingView | Sep 28, 2026 | neutral | 0 | 0.6 |
| 10x Genomics (TXG) Stock Could Look Pricey Against Its Current Sales Base - Simply Wall Street | 10x Genomics (TXG) Stock Could Look Pricey Against Its Current Sales Base Simply Wall Street | View source ↗ | Simply Wall Street | Sep 25, 2026 | neutral | 0 | 0.6 |
| TXG Stock Rallies As AI Deal And Legal Win Shift Outlook - StocksToTrade | TXG Stock Rallies As AI Deal And Legal Win Shift Outlook StocksToTrade | View source ↗ | StocksToTrade | Sep 24, 2026 | neutral | 0 | 0.6 |
| TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences - Yahoo Finance | TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences Yahoo Finance | View source ↗ | Yahoo Finance | Aug 31, 2026 | neutral | 0 | 0.6 |
| 10x Genomics (TXG): Doubled, Then Doubled Again - Hedgeye | 10x Genomics (TXG): Doubled, Then Doubled Again Hedgeye | View source ↗ | Hedgeye | Aug 10, 2026 | neutral | 0 | 0.6 |
| 10x Genomics (TXG) Stock Rally Leans On Margin Gains And Cash - Simply Wall Street | 10x Genomics (TXG) Stock Rally Leans On Margin Gains And Cash Simply Wall Street | View source ↗ | Simply Wall Street | Aug 7, 2026 | neutral | 0 | 0.6 |
| Why Is 10x Genomics (TXG) Stock Soaring Today - StockStory | Why Is 10x Genomics (TXG) Stock Soaring Today StockStory | View source ↗ | StockStory | Jun 24, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.